Pantok Forte (Simvastatin)

Simvastatin, the active ingredient in Pantok Forte, is a HMG‑CoA reductase inhibitor presented as a tablet for oral use. It lowers elevated cholesterol and triglyceride levels in adults at risk of cardiovascular disease. GNH USA supplies Pantok Forte as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Pantok Forte (simvastatin) acts on lipid metabolism pathways to manage dyslipidaemia. It is indicated for: - Hypercholesterolaemia: reduces low‑density lipoprotein (LDL) cholesterol and total cholesterol. - Mixed hyperlipidaemia: lowers triglycerides and raises high‑density lipoprotein (HDL) cholesterol. - Primary prevention of cardiovascular events: decreases risk of heart attack, stroke and related mortality. - Familial hypercholesterolaemia (heterozygous): helps achieve target LDL‑C levels when combined with diet and lifestyle measures.

Adverse reactions to simvastatin vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Myalgia: muscle aches without weakness. - Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia. - Elevated liver enzymes: mild transaminase rise. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with possible renal impairment. - Hepatotoxicity: marked elevation of liver transaminases or bilirubin. - Severe allergic reactions: rash, pruritus, angio‑edema or anaphylaxis. - Acute kidney injury: secondary to rhabdomyolysis or other mechanisms. - Thrombocytopenia: unexplained low platelet count. - Interstitial lung disease: rare inflammatory lung involvement.

When prescribing Pantok Forte, clinicians should consider several safety aspects. - Liver function monitoring: obtain baseline and periodic ALT/AST levels. - Muscle toxicity vigilance: educate patients to report unexplained muscle pain or weakness. - Drug‑interaction review: avoid concomitant use with strong CYP3A4 inhibitors. - Pregnancy and lactation: contraindicated in pregnancy; assess risk‑benefit in breastfeeding. - Renal impairment: dose adjustment may be required in severe renal dysfunction. - Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture and direct sunlight.

Simvastatin participates in multiple pharmacokinetic and pharmacodynamic interactions.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): markedly increase simvastatin exposure and risk of rhabdomyolysis. - Gemfibrozil: synergistic effect on muscle toxicity. - Cyclosporine: elevates plasma concentrations, raising myopathy risk.

Moderate Interactions (Monitor Closely): - Antacids (aluminum‑ or magnesium‑containing): may modestly reduce absorption. - Warfarin: may enhance anticoagulant effect; monitor INR. - Niacin (high dose): additive effect on liver enzymes. - Digoxin: potential increase in serum levels. - St. John’s wort: may reduce simvastatin concentrations.